Related Experiment Video
Updated: Aug 11, 2026
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
99mTechnetium-C595 radioimmunoscintigraphy: a potential staging tool for bladder cancer
M S Simms1, A C Perkins, M R Price
1Department of Urology, City Hospital Nottingham, UK. msimms@gertrude42.freeserve.co.uk
Objectives:
To assess whether immunoscintigraphy using a conjugate of the anti-MUC1 monoclonal antibody C595 and 99mTc could be used to target transitional cell bladder cancer after intravenous administration to patients.
Patients And Methods:
Twenty-one patients with invasive or metastatic transitional cell carcinoma were recruited. Patients received 1 mg of C595 labelled with 800 MBq 99mTc followed by imaging at 0.5, 6 and 24 h using a combination of planar and single-photon emission computed tomography. Of these patients, 14 subsequently underwent cystectomy, four underwent radiotherapy and the remaining three had histologically confirmed metastatic disease. The results of immunoscintigraphy were compared with surgical findings and conventional radiology.
Results:
There were no adverse reactions in any patient. Of the 20 patients who were found to have tumour at the time of the study, positive localization of antibody in tumour was apparent in 16. Of the remaining four patients, false-positive localization of antibody in presumed nodal tissue was detected in two. The remaining scan results were equivocal. In three patients, histologically confirmed pelvic nodal metastases that had not been detected on preoperative computed tomography were identified.
Conclusion:
These early results show the potential of 99mTc-C595 immunoscintigraphy for staging bladder cancer. A larger study is needed to fully evaluate the technique.
Insights
Technetium-99m-labeled C595 antibody immunoscintigraphy shows promise for staging bladder cancer. This technique accurately identified tumors in 16 of 20 patients, aiding in the detection of metastases.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunodiagnostics
Background:
- Transitional cell carcinoma is the most common type of bladder cancer.
- Accurate staging is crucial for effective treatment planning.
- Current imaging modalities may not always detect small or metastatic lesions.
Purpose of the Study:
- To evaluate the efficacy of immunoscintigraphy using a technetium-99m (99mTc) labeled anti-MUC1 monoclonal antibody (C595) for targeting transitional cell bladder cancer.
- To assess the diagnostic accuracy of 99mTc-C595 immunoscintigraphy in patients with invasive or metastatic bladder cancer.
Main Methods:
- Twenty-one patients with invasive or metastatic transitional cell carcinoma received intravenous administration of 1 mg of 99mTc-labeled C595 (800 MBq).
- Imaging was performed at 0.5, 6, and 24 hours post-injection using planar and single-photon emission computed tomography (SPECT).
- Results were compared with surgical findings and conventional radiology, including computed tomography (CT).
Main Results:
- No adverse reactions were reported in any of the 21 patients.
- Positive antibody localization in tumor was observed in 16 out of 20 patients with detectable tumors.
- Immunoscintigraphy identified histologically confirmed pelvic nodal metastases in three patients missed by preoperative CT scans.
- False-positive localization in presumed nodal tissue occurred in two patients.
Conclusions:
- 99mTc-C595 immunoscintigraphy demonstrates potential as an adjunct tool for staging bladder cancer.
- The technique showed improved detection of nodal metastases compared to conventional CT.
- Further larger-scale studies are warranted to fully validate the clinical utility of this immunoscintigraphy approach.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:27Imaging Studies III: Computed Tomography